Pharmacogenetics of Glucagon-like Peptide-1 agonists for the treatment of Type 2 Diabetes Mellitus.

CONCLUSION: Although the exact DNA sequences that cause the molecular changes leading to a variable response to GLP-1 agonists have not been yet fully identified, these findings underline the importance of an individualized approach in anti-diabetic treatment. PMID: 29473524 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29473524?dopt=Abstract

Source: Current Clinical Pharmacology - February 21, 2018 Category: Drugs & Pharmacology Authors: Karras S, Rapti E, Koufakis T, Kyriazou A, Goulis D, Kotsa K Tags: Curr Clin Pharmacol Source Type: research